Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689516 | 0.83 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL15631746 | 0.79 | CTSK (0.38) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL10892359 | 0.77 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL11216968 | 0.77 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3185669 | 0.77 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL1089194 | 0.77 | DGAT1 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL13826663 | 0.75 | CTSL (0.43) | CA1CA2CA7CTSKMEN1 | |
| SCHEMBL12944842 | 0.74 | TGFBR1 (0.35) | DGAT1CA1CA2CA7CTSK | |
| SCHEMBL15631724 | 0.74 | CTSK (0.44) | CA1CA2CA7CTSKMEN1 | |
| SCHEMBL29713780 | 0.74 | CA1 (0.37) | CA12CA14CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453037-B2 | Methylphenidate-prodrugs, processes of making and using the same | KEMPHARM, INC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMMAVE THERAPEUTICS SA (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266911-A1 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | COMT, TPMT, PNMT | CA12 3562/4885CA14 2362/4885DGAT1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.